Four clinical trials evaluating this combination have commenced, and data obtained so far suggest this approach as a promising route to indirectly target KRAS-mutant cancers (NCT03981614, NCT02022982, NCT03170206, and NCT04615312). This evidence concerns the gene KRAS and cancer.